Avidity Biosciences

Avidity Biosciences is a biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease. Avidity Biosciences, (formerly NASDAQ: RNA/RNAM) is no longer a publicly traded company. Novartis acquired Avidity.